Clinic Roundup

• EyeGate Pharma Inc., of Waltham, Mass., said it started enrolling patients with anterior scleritis in its Phase I study of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL). The randomized study will enroll up to 24 subjects with noninfectious, non-necrotizing anterior scleritis and will test the product's safety and tolerability at three ocular iontophoresis dose levels. Partial funding for the study is provided by an FDA orphan drug indication grant.